Nucleoside Metabolic Inhibitor [EPC]

209817 reported adverse events

Drugs of this class: FLUOROURACIL DECITABINE AZACITIDINE CAPECITABINE CYTARABINE CLOFARABINE NELARABINE (DAUNORUBICIN AND CYTARABINE) LIPOSOME CEDAZURIDINE AND DECITABINE GEMCITABINE PENTOSTATIN

These side effects are most commonly reported by patients taking drugs of the Nucleoside Metabolic Inhibitor [EPC] class:

#	Side effect	Count
0	DIARRHOEA	19156
1	DEATH	15493
2	NAUSEA	14065
3	NEUTROPENIA	11347
4	FEBRILE NEUTROPENIA	11320
5	VOMITING	11023
6	DISEASE PROGRESSION	10489
7	FATIGUE	10141
8	PYREXIA	9923
9	THROMBOCYTOPENIA	8510

See all common reactions for Nucleoside Metabolic Inhibitor [EPC]

Drugs of the Nucleoside Metabolic Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY	147	0.8647
1	ACUTE MYELOID LEUKAEMIA RECURRENT	523	0.4373
2	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY	168	0.4138
3	CAECITIS	166	0.3689
4	MYELODYSPLASTIC SYNDROME TRANSFORMATION	178	0.3633
5	PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME	6314	0.3623
6	NEUTROPENIC COLITIS	414	0.3301
7	TRANSFORMATION TO ACUTE MYELOID LEUKAEMIA	131	0.3134
8	DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT	328	0.3121
9	MYCOBACTERIUM CHELONAE INFECTION	156	0.3120

See all enriched reactions for Nucleoside Metabolic Inhibitor [EPC]